Latest Operating Expenses News

Acrux Limited’s FY26 receipts soared 960% to $5 million, fuelled by licensing milestones and growing generic sales, while FDA guidance clears the way for pivotal Phase III trials of its Female Testosterone therapy.

Decidr AI Industries accelerated its commercial growth with a 71% jump in annualised exit-rate revenue to $13.6 million and bolstered its cash position to $23.4 million following a $14.2 million equity raise.

archTIS surged to a record FY2026 with Annual Recurring Revenue hitting $14.8 million, driven by major US and Australian Defence wins and expanding its customer base beyond defence.

Tissue Repair advances its US Phase III chronic wound trial with 100 patients randomised and targets October FDA 510(k) submission. The company reports a robust cash position bolstered by R&D refunds and has cut manufacturing scale-up costs.

Enlitic slashed its net operating cash outflow by 76% in Q2 FY26 and secured binding commitments for a A$15 million conditional placement alongside convertible note conversions, positioning the company with a pro forma cash balance of about A$18 million and a debt-free balance sheet.

Omni Bridgeway delivered a standout FY26 with record investment proceeds and new commitments, underpinned by disciplined cost management and a robust pipeline.

Resouro Strategic Metals has filed a comprehensive NI 43-101 Technical Report that underpins its Preliminary Economic Assessment for the Tiros Titanium and Rare Earths Project in Brazil, confirming robust economics and a capital-efficient staged development strategy.

BetMakers Technology Group delivered a robust Q4 FY26 with revenue rising 9.4% to $24.2 million and adjusted EBITDA nearly doubling to $4.5 million, driven by new commercial deals and operational efficiencies.

BCAL Diagnostics has strengthened its leadership, advanced breast cancer detection tests, and secured key funding and strategic investments to underpin its FY2027 growth plans.

Beforepay Group capped FY26 with a robust quarter, delivering record net transaction margins and a significant new credit facility that cuts funding costs.

Xenitra Limited (ASX:XEN) has turned around its cash flow in Q4 FY26, reporting positive operating cash flow of A$0.8 million driven by a leaner cost base and a shift towards higher-margin OTC medicines and blockchain-enabled OPAL tokenised sales.

N1 Holdings delivered a record quarter for settlement volumes and cash receipts despite a tough interest rate environment, driving a 10% rise in FY26 revenue to $21.67 million and $1.21 million net profit before tax.